Barclays analyst Peter Lawson downgraded Prelude Therapeutics to Underweight from Equal Weight with an unchanged price target of $3. Prelude’s upcoming catalysts are “intriguing,” but the firm currently finds them “hard to derisk” and sees limited upside in the next 12 months along with greater upside potential across its coverage universe, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics Unveils Educational SMARCA Series
- Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
- Prelude Therapeutics files $400M mixed securities shelf
- Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
- Prelude Therapeutics’ Legal Peril: Navigating Corruption Risks in China and Taiwan